Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Indolinone. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN115353511A details a novel Pd-catalyzed multi-component synthesis for carbonyl-bridged biheterocycles, offering cost reduction in API manufacturing and scalable routes.
Patent CN115353511A details a safe, multi-component synthesis for carbonyl-bridged biheterocycles using in-situ CO generation, offering significant cost reduction in API manufacturing.
Novel palladium-catalyzed carbonylation method for synthesizing carbonyl-bridged biheterocycles without toxic CO gas, offering safer pharmaceutical intermediate manufacturing.
Patent CN115353511A details a safe, one-pot synthesis of carbonyl-bridged biheterocycles using in-situ CO generation, offering reliable pharmaceutical intermediate supply.
Patent CN115286556B enables high-purity indolinone ester production using green solvents and catalysts, reducing lead time while enhancing supply chain reliability for pharma intermediates.
Patent CN115286556B introduces a green palladium-catalyzed method using dimethyl carbonate and formic acid for indolinone-based intermediates with enhanced scalability and reduced environmental impact.
Patent CN113735756B enables high-yield enantioselective isoindolinone production under mild conditions enhancing supply chain reliability for pharmaceutical intermediates
This patent discloses a novel rhodium-catalyzed method achieving high-yield enantioselective synthesis of chiral isoindolinones with significant cost reduction potential and enhanced supply chain reliability for pharmaceutical manufacturing.
Patent CN118878452B enables high-yield synthesis under mild conditions with significant cost savings for reliable pharmaceutical intermediate supply chains.
Patent CN115286556B enables sustainable production of indolinone esters using dimethyl carbonate as dual solvent/reactant with significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN107840819B enables efficient one-step synthesis of high-purity isoindolinone derivatives, offering significant cost reduction and reliable supply chain for pharmaceutical intermediates manufacturing.
Patent CN113735756B enables efficient chiral isoindolinone synthesis under mild conditions with up to 95% ee, delivering substantial cost savings and enhanced supply chain reliability for pharmaceutical manufacturers.
Patent CN105294536A enables efficient synthesis of high-purity pharmaceutical intermediates through palladium-catalyzed C-H activation with substantial cost reduction and enhanced supply chain reliability for global manufacturers.
Patent CN107573276B enables high-purity indolinone synthesis via NHC catalysis, reducing lead time and costs while ensuring reliable supply chain for pharmaceutical intermediates.
Patent CN107573276B enables high-purity indolinone intermediates through green NHC catalysis with one-pot processing reducing lead time and manufacturing costs.
Palladium-catalyzed C-H activation method enables high-purity 3-iminoisoindolinone production with significant cost reduction and reliable supply chain for pharmaceutical manufacturers.
Patent CN113735756A enables high-yield enantioselective synthesis under mild conditions, enhancing supply chain reliability and reducing pharmaceutical manufacturing costs.
Recent patent literature demonstrates a Ni(II)-catalyzed one-step synthesis of 3-ether isoindolinone intermediates with 88-98% yield, enabling cost reduction in API manufacturing and supply chain stability.
Solve chiral isoindolinone synthesis challenges: 91% yield, 95% ee, mild conditions. Reduce costs & supply risks with scalable CDMO expertise.
Discover a novel, high-yield synthesis method for spiro[indene-isoindolinone] compounds with mild reaction conditions. Ideal for pharmaceutical R&D and production, reducing costs and safety risks.